Kongruang A.Limsuwanachot N.Magmuang S.Areesirisuk P.Niparuck P.Siriboonpiputtana T.Rerkamnuaychoke B.Mahidol University2023-09-172023-09-172023-12-01Hematology (Amsterdam, Netherlands) Vol.28 No.1 (2023) , 2256199https://repository.li.mahidol.ac.th/handle/20.500.14594/90056OBJECTIVES: We performed a feasibility study of an FDA-approved commercial ddPCR assay to measure BCR::ABL1 in CML patients treated using TKI therapy. METHODS: Assay performance of standard RQ-PCR and commercially available FDA-approved ddPCR were compared to measure BCR::ABL1 p210 transcripts in RNA samples from 100 CML patients who received TKI therapy. RESULTS: %BCR::ABL1/ABL1IS levels obtained from both methods were not statistically significant difference after normalization with batch-specific conversion factor (p = 0.0651). The correlation and agreement of %BCR::ABL1/ABL1IS between the two assays were high. Molecular response stratification data showed 56% concordance between RQ-PCR and ddPCR, and 37% higher residual disease detection using ddPCR. Furthermore, 21.21% (7/33) of RQ-PCR undetectable samples were detected by ddPCR, representing high sensitivity to quantify the low abundance of BCR::ABL1 transcripts. CONCLUSION: ddPCR was proven to be a highly sensitive method with the potential to overcome some limitations of traditional RQ-PCR, and has the potential of being a valuable tool for monitoring BCR::ABL1 transcripts in CML during TKI therapy. (163 words).MedicineArticleSCOPUS10.1080/16078454.2023.22561992-s2.0-851704892651607845437695125